PIE Polskie Innowacje Energetyczne Spółka z Ograniczoną Odpowiedzialnością (KRS 0000485035, NIP 9452176334) is a Polish company, headquartered in Kraków, Małopolskie voivodeship. PIE POLSKIE INNOWACJE ENERGETYCZNE operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since November 7, 2013. PIE POLSKIE INNOWACJE ENERGETYCZNE's most recently reported net revenue was 3.0 M PLN for 2024.
Negative equity
Negative equity in 1 of 7 available reporting years.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - PIE Polskie Innowacje Energetyczne
Identity
- Name
- PIE Polskie Innowacje Energetyczne Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- November 7, 2013
- Registry status as of
- June 18, 2026
- Latest entry
- June 18, 2026
- Founding act
- 15.12.2014R., REP.A NR 1390/2014, NOTARIUSZ KATARZYNA OZGA-DOMAGALSKA, KANCELARIA NOTARIALNA W KRAKOWIE, ZMIANA § 1 UST.…
Articles of association history (2)
- 06-11-2013
- December 15, 2014: 15.12.2014R., REP.A NR 1390/2014, NOTARIUSZ KATARZYNA OZGA-DOMAGALSKA, KANCELARIA NOTARIALNA W KRAKOWIE, ZMIANA § 1 UST.2, § 4 DODANIE PKT.15, 16, 17 I 18.
Activities
Main activity
72.19.ZOther research and experimental development on natural sciences and engineering
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Address and contact
- Address
- KUŹNICY KOŁŁĄTAJOWSKIEJ, 13, 210, 31-234, KRAKÓW, POLSKA
- Voivodeship
- MAŁOPOLSKIE
- District
- M. KRAKÓW
- BIURO@PIESA.PL
- Website
- WWW.PIESA.PL
- E-delivery address
- AE:PL-52229-85705-VDACE-32
Risk and payment profile - PIE Polskie Innowacje Energetyczne
Credibility rating
78.1 / 100
Good credibility
Insolvency risk
Very low
Low threat
Closure risk
1
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
2
2/13 yrs
Board changes
1
1/13 yrs
PKD changes
1
1/13 yrs
Name changes
1
1/13 yrs
Data from 13 years of registry activity.
Credibility history
Payment reliability score from 2018–2024
Current: B (78/100)
Trend: improving (+23.9 pts/year)
High payment credibility - the company's financial condition is good and the risk of cooperating with it is low.
Trade credit limit history
Standard limit from 2018–2024
Current: 503.5 K PLN
Safe: 327.3 K PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - PIE Polskie Innowacje Energetyczne
Founded
November 7, 2013
12 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
KRAKÓW
MAŁOPOLSKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
10.0 K PLN
100 shares total
Shareholders
1
shareholder
Board
1 person
Filed years
7 years
2018–2024 · profitable: 3/7
Registry entries
37
latest: June 18, 2026
Risk signals
Revenue
3.0 M PLN
2024
Net profit
589.4 K PLN
2024
Assets
2.8 M PLN
2024
Equity
1.2 M PLN
2024
EBITDA
256.6 K PLN
2024
Valuation
2.4 M PLN
Medium confidence
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - PIE Polskie Innowacje Energetyczne.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Captor Therapeutics: PLN 36 m of cash at 30 September 2025, runway to mid-2026 - clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
